In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the ‘summary of the operation’ below, containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.<\/p>\n
Names of the companies and groups concerned:<\/strong><\/p>\n Nature of the operation<\/strong><\/p>\n Economic sectors concerned<\/strong><\/p>\n Deadline for interested third parties to submit their observations<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council has received notification of a project for an economic concentration operation concerning the acquisition by the company ‘Moroccan Therapeutic Company SA’ of the pharmaceutical assets related to the brand and products of CIALIS from ‘Eli Lilly and Company’.<\/p>\n ‘Moroccan Therapeutic Company SA’ is a Moroccan joint stock company, with its registered office at Quartier Industriel Bouskoura – Bouskoura 27182, registered with the Casablanca Trade Register under number 35631. It specializes in the manufacture and commercialization of medicines.<\/p>\n ‘Eli Lilly and Company’ is a company registered in the State of Indiana, with its headquarters at Lilly Corporate Center, Indianapolis, Indiana, United States 46285. It is active in the research, development, manufacture, and commercialization of pharmaceutical products.<\/p>\n <\/p>\n Done in Rabat on December 3, 2025<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the ‘summary of the operation’ below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups concerned: The acquirer: ‘Moroccan Therapeutic Company SA’; Targeted assets: Pharmaceutical assets related to the brand and products of CIALIS from ‘Eli Lilly and Company’. Nature of the operation Acquisition of asset elements. Economic sectors concerned Market for drugs used in the treatment of erectile dysfunction. Deadline for interested third parties to submit their observations 10 days from the date of publication of this press release, i.e. December 15, 2025. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council has received notification of a project for an economic concentration operation concerning the acquisition by the company ‘Moroccan Therapeutic Company SA’ of the pharmaceutical assets related to the brand and products of CIALIS from ‘Eli Lilly and Company’. ‘Moroccan Therapeutic Company SA’ is a Moroccan joint stock company, with its registered office at Quartier Industriel Bouskoura – Bouskoura 27182, registered with the Casablanca Trade Register under number 35631. It specializes in the manufacture and commercialization of medicines. ‘Eli Lilly and Company’ is a company registered in the State of Indiana, with its headquarters at Lilly Corporate Center, Indianapolis, Indiana, United States 46285. It is active in the research, development, manufacture, and commercialization of pharmaceutical products. Done in Rabat on December 3, 2025<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-38683","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n